News Room

April 3, 2019

Veterinary Oncology Licensing Agreement Signed Between SourcingLink.net and NanoSmart Pharmaceuticals, Inc.

SourcingLink.net, Inc. (SNET), a San Francisco, CA based company, announced today that it entered into an exclusive, worldwide licensing agreement with NanoSmart Pharmaceuticals, Inc (NanoSmart) for the right to use NanoSmart's Anti-Nuclear Antibody (ANA)-targeted drug delivery technologies to develop and commercialize chemotherapy drug formulations for veterinary oncology.

March 25, 2019

SourcingLink.net Enters Into an Exclusive Worldwide Licensing Agreement with NanoSmart for ANA-Targeted Doxorubicin Formulations to Treat Cancer

SourcingLink.net, Inc. (SNET), announced today that it entered into an exclusive worldwide licensing agreement with NanoSmart for the right to use NanoSmart’s nanoparticle platform technologies to develop and commercialize improved formulations of doxorubicin for the treatment of human cancers. The license includes access to one of NanoSmart's lead drug formulations, ANA-Conjugated Liposomal Doxorubicin, which has been previously granted Orphan Drug Designation by the US Food and Drug Administration. Under the terms of the agreement, NanoSmart will receive an upfront fee, restricted common shares of SNET stock, an annual maintenance fee, and a high single-digit royalty on net sales of formulations that incorporate NanoSmart's intellectual property. 

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration (FDA) for a second drug product that uses NanoSmart’s proprietary drug delivery platform. The drug product is a formulation of dactinomycin for the treatment of Ewing’s sarcoma, a rare type of childhood bone cancer. The FDA granted NanoSmart’s Orphan Drug Designation on the basis of a plausible hypothesis that the novel formulation may be clinically superior to the original drug.

NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer

July 30, 2015

February 9, 2015

NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing’s Sarcoma

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration (FDA) for a second drug product that uses NanoSmart’s proprietary drug delivery platform. The drug product is a formulation of dactinomycin for the treatment of Ewing’s sarcoma, a rare type of childhood bone cancer. The FDA granted NanoSmart’s Orphan Drug Designation on the basis of a plausible hypothesis that the novel formulation may be clinically superior to the original drug.

© 2020 by NanoSmart Pharmacueticals, Inc.

Terms and Conditions

Privacy Policy